Emerging evidence has demonstrated that CD160 participates in CLL pathogenesis by activating PI3K/Akt-independent pathways and inhibiting apoptosis, consequently activating tumor proliferation and inducing resistance to apoptosis. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.